SNK 01
Alternative Names: SNK-01; SNK01 - NKGen BiotechLatest Information Update: 02 Aug 2024
At a glance
- Originator NKGen Biotech
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Alzheimer's disease; Solid tumours
- Preclinical Triple negative breast cancer